Physician profile
Celeste E Pottorff
NPI 1780875799
$2,087.75
in general payments reported to CMS, 2019-2025
28 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $47.32 · 2021: $95.70 · 2022: $466 · 2023: $484 · 2024: $524 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.06 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $232.51 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Organon LLC | $228.05 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $213.40 | 2021-2024 | |
| Abbvie INC. | $162.03 | 2019-2022 | |
| Millicent US INC | $143.25 | 2023-2025 | Femring, Intrarosa |
| Astellas Pharma US INC | $120.56 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $103.92 | 2019-2025 | Gardasil 9, Enflonsia |
| Bayer Healthcare Pharmaceuticals INC. | $89.14 | 2019-2023 | |
| Coopersurgical, INC. | $89.12 | 2021-2024 | Paragard T 380a |
| Biogen, INC. | $84.91 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $81.60 | 2019-2022 | |
| Pfizer INC. | $67.03 | 2024-2025 | |
| Channel Medsystems, INC. | $60.59 | 2023 | |
| Myriad Women'S Health, INC. | $58.65 | 2023 | Myrisk |
| Baxter Healthcare | $45.76 | 2024 | Perclot |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $44.00 | 2024 | Ova1 |
| Daiichi Sankyo INC. | $42.31 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $38.41 | 2024-2025 | Myfembree |
| Exeltis, USA INC. | $28.10 | 2019-2022 | |
| Avion Pharmaceuticals | $25.50 | 2022 | |
| Gynesonics, INC. | $22.34 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Smith+Nephew, INC. | $18.05 | 2024 | Pico 14, Pico 7 |
| Dexcom, INC. | $18.00 | 2025 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $15.31 | 2022 | |
| Solventum Corporation | $14.12 | 2025 | |
| Seqirus USA INC | $13.91 | 2024 | Flucelvax |
| Minerva Surgical, INC | $13.60 | 2019 | |
| Lupin INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Pottorff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.